Skip to main content

Advertisement

Table 1 Individual patients characteristics

From: Pulmonary vein isolation in patients with paroxysmal atrial fibrillation is associated with regional cardiac sympathetic denervation

Individual number Sex Age Duration of AF (years) CHD LA volume (ml) AA drug treatment before PVI Duration of radiofrequency impulses (seconds) Relapse AA Drug treatment after PVI
1 F 51 2 One vessel CHD 99 Sotalol 56 Yes, re-PVI Sotalol
2 M 55 10 No CHD 122 Beta blocker 41 Yes, re-PVI Beta blocker
3 F 67 7 No CHD 123 Beta blocker, dronedarone 61 Yes, re-PVI Beta blocker, dronedarone
4 M 44 13 No CHD 72 Beta blocker 40 None Beta blocker, flecainide
5 F 56 4 No CHD 118 Beta blocker, flecainide 79 None Beta blocker, flecainide
6 M 54 1 No CHD 76 Beta blocker, flecainide 61 None Beta blocker, flecainide
7 M 72 17 No CHD 82 Beta blocker, dronedarone 69 None Beta blocker, dronedarone
8 M 69 3 three vessel CHD 183 Beta blocker 98 Yes, re-PVI Beta blocker, dronedarone
9 M 64 2 No CHD 125 Beta blocker, flecainide 91 None Beta blocker, propafenone
10 F 49 5 No CHD 82 Beta blocker, flecainide 81 None Beta blocker, flecainide
11 M 48 1 No CHD 116 Beta blocker, dronedarone 43 None Dronedarone
12 F 70 2 No CHD N/A Beta blocker, dronedarone 40 Yes, no re-PVI Beta blocker, flecainide
13 M 52 5 No CHD 103 Beta blocker, flecainide 33 None Beta blocker, flecainide
14 M 40 1 No CHD 52 Beta blocker 41 None Beta blocker, flecainide
15 M 61 4 No CHD 115 Beta blocker, flecainide 49 None Beta blocker, flecainide
16 M 52 5 No CHD 103 Beta blocker, flecainide 51 None Beta blocker, flecainide
  1. CHD, chronic ischemic heart disease; LA, left atrium; AA, antiarrhythmic, N/A not applicable.